Connecticut Cannabis Sales Reach $22 Million in March
Recreational and medical cannabis in Connecticut have profited $22.1 million in sales in March 2023.
In March 2023, the recreational and medical cannabis market in Connecticut have generated $22.1 million in sales (1). This is a 20% increase from the previous month.
First launched on January 10th, Adult-use sales accounted for nearly 43% of the total. The previous month, February, recreational cannabis use transactions held 38% of the $18,466,141 in total cannabis sales in the state.
Connecticut has 5 dispensaries transitioning to recreational sales throughout the state. Since January 2023, medical cannabis patients have decreased by about 2,300. The number of medical cannabis patients in the state is nearly 47,000, according to state data (1). This gap in sales between recreational and medical cannabis could shorten in the months to come. Pricing for adult-use cannabis has decreased by 8% since January while, medical cannabis products have stayed stagnant at $36.55.
Cannabis retailers in Connecticut are anticipated to bring in $200 million in recreational transactions and generate $149 million in medical cannabis sales, according to MJBiz’s recently released 2023 Factbook (2).
References
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Khan
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
German Medical Cannabis Market Has Yet to Reach Its Full Potential
December 25th 2024Germany’s Cannabis Act (CanG) is beginning to transform the country's medical cannabis market, with potential opportunities to expand telemedicine, improve physician training, and enhancing accessibility in this rapidly growing industry.
